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Abstract:  9 
Inducing macromolecular interactions with small molecules to activate cellular signaling is a 10 
challenging goal. PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that 11 
recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. 12 
Structural elucidation of the key ternary species ligase:PROTAC:target and how this impacts 13 
target degradation selectivity remains elusive. We solved the crystal structure of Brd4-14 
degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4BD2). The 15 
ligand folds into itself to allow formation of specific intermolecular interactions in the ternary 16 
complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and 17 
proximity assays, are consistent with pronounced cooperative formation of ternary complexes 18 
with Brd4BD2. Structure-based designed compound AT1 exhibits highly selective depletion of 19 
Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate 20 
preferential recruitment of a target protein into stable and cooperative complex with an E3 21 
ligase for selective degradation.  22 
 23 
  24 
 2
Introduction 25 
Regulating protein function through targeted degradation as opposed to more conventional 26 
target inhibition has emerged as a new modality of discovery chemistry with attractive 27 
potential both as tools for target validation and for the development of novel therapeutics 1-4. 28 
PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that bring a target 29 
protein into spatial proximity with an E3 ubiquitin ligase to trigger target ubiquitination and 30 
subsequent proteasomal degradation 5-11. Recent developments in the field have led to 31 
PROTACs being designed with increasingly “drug-like” molecular properties, and 32 
remarkable activities both in cells and in vivo 10. Furthermore, we and others have shown that 33 
target depletion selectivity by PROTACs can significantly exceed the binding selectivity of 34 
their constitutive warhead ligands 7,12. This realization provides proof-of-concept for turning 35 
non-selective or promiscuous ligands into more selective degraders, which can be highly 36 
desirable for both chemical probes and drug leads. A characteristic feature of PROTACs 37 
mode of action is their sub-stoichiometric catalytic action that alleviates the requirement for 38 
target engagement and occupancy of traditional inhibitors 9. Effective redirection of a ligase 39 
poly-ubiquitination activity toward a new substrate protein requires formation of a ternary 40 
complex ligase:PROTAC:target, an intermediate species that is crucial to the cellular activity 41 
of degrader molecules. However, structural elucidation of such ternary species and how it 42 
may influence selectivity of target degradation remain elusive since the PROTAC concept 43 
was first incepted and demonstrated in 2001 (ref. 5).  44 
In 2015 we and others reported the first examples of small-molecule PROTACs that target 45 
the bromo- and extra-terminal (BET) family proteins for degradation by recruiting substrate-46 
recognition subunits von Hippel–Lindau protein (VHL) 7 and cereblon (CRBN) 6,8 of the 47 
respective cullin RING ligases (CRLs), CRL2VHL and CRL4CRBN. Compound MZ1 (ref. 7) 48 
conjugates the pan-BET inhibitor JQ1 (ref. 13) to VH032, a potent and specific VHL ligand 49 
14,15, via a 3-unit PEG linker (Fig. 1a). MZ1 and its analogues, MZ2 and MZ3 50 
(Supplementary Results, Supplementary Fig. 1), induce more effective depletion of a 51 
single BET member, Brd4 (a validated drug target against cancer and other diseases 16), over 52 
its family paralogues Brd2 and Brd3 (ref. 7). These observations led us to hypothesize a 53 
structural basis for target selectivity, imparted as a result of PROTAC-induced recruitment of 54 
the ligase and bromodomain together in a ternary complex. To reveal the molecular details of 55 
complex formation, we pursued the crystal structure of MZ1 in complex with VHL and a 56 
BET bromodomain. Here we present for the first time a structure of a PROTAC bound to 57 
both E3 ligase and target protein. The structure reveals MZ1 is “sandwiched” between the 58 
two proteins, inducing extensive new protein-protein and protein-ligand contacts of both 59 
hydrophobic and electrostatic nature. Biophysical binding studies in solution allowed 60 
measurement of full thermodynamics parameters of complex formation, which revealed 61 
marked isoform-specific cooperativity of ternary complexes. Surface mutagenesis swap and 62 
proximity binding assays data support the induced PPI contacts drive specificity of the 63 
cooperative recognition, impacting on the relative population of ternary complexes. 64 
Furthermore, new PROTAC molecules designed guided by the crystal structure showed 65 
exquisite selectivity for inducing cellular depletion of Brd4 over its BET family members 66 
Brd2 and Brd3.  67 
Results  68 
Ternary complex crystal structure. To elucidate the structural details of PROTAC-induced 69 
substrate recruitment to an E3 ligase, we solved the crystal structure of MZ1 bound in a 70 
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ternary complex with the second bromodomain (BD) of Brd4 (Brd4BD2) and VHL to 2.7 Å 71 
resolution (Fig. 1a, Supplementary Table 1). The asymmetric unit of the crystal contained 72 
two ternary Brd4BD2:MZ1:VCB (VHL, ElonginB and ElonginC) complexes of overall 73 
identical quaternary architecture (Supplementary Fig. 2a) and only minor deviations at 74 
either end when superposed over the central VHL subunit (Supplementary Fig. 2b,c). The 75 
first complex (chains A, B, C and D) had lower average B factors (Supplementary Fig. 2a) 76 
so we refer to this in all subsequent analyses. The electron density around MZ1 was fully 77 
defined (see inset panel in Fig 1a and Supplementary Fig. 2d,e for each protomer in the 78 
asymmetric unit). MZ1 is bound within a bowl-shaped interface formed by extensive protein-79 
protein interactions (PPIs) between Brd4BD2 and VHL (Supplementary Fig. 3a). The bowl 80 
has a hydrophobic "base" which is formed by two key points of contact (Fig. 1b and 81 
Supplementary Fig. 3a). Firstly, Trp374 from the characteristic hydrophobic region named 82 
“WPF shelf” (ref. 17) of Brd4BD2 interacts with residues Arg69, Pro71 and Tyr112 of VHL 83 
(Fig. 1b). Pro71 provides an additional stack to the WPF, forming an extended “PWPF” shelf 84 
(Fig. 1b). Secondly, Ala384 and Leu385 from the second helical turn of the ZA loop of 85 
Brd4BD2 contact the hydrophobic side chains of Arg108, Ile109 and His110 in β4 of VHL 86 
(Fig. 1b). Two electrostatic "arms" complete the rim of the bowl. At one end, Asp381 and 87 
Glu383 in the ZA loop of Brd4BD2 form a tight zipper structure of complementary charges 88 
with Arg107 and Arg108 (Fig. 1c). At the opposite end Brd4BD2 residue Glu438, residing in 89 
the BC loop, contacts Arg69 from VHL (Fig. 1d). In the induced interface between the two 90 
proteins, Brd4BD2 recapitulates some of the interactions made by the HIF-1α CODD segment 91 
peptide with VHL 18,19, as the electrostatic zipper structure generated by Asp381 and Glu383 92 
contacts the same VHL residues (Arg107 and Arg108) as Asp569 and Asp571 of HIF-1α 93 
(Fig. 1c and Supplementary Fig. 3b,c). In contrast, VHL does not contact the surface of 94 
Brd4 bromodomain bound to acetyllysine histone H4 peptide 20 (Supplementary Fig. 3d,e). 95 
In total the PPIs induced in the complex bury a surface area of 688 Å2 (Supplementary 96 
Table 2). 97 
MZ1 is cupped within the bowl structure in such a way that its two heads recapitulate the 98 
binding modes of the respective ligands individually – JQ1 in the acetyllysine-binding pocket 99 
of Brd4BD2 13,20, and VH032 in the hydroxyproline-binding site of VHL 14 (Supplementary 100 
Fig. 3f,g). In addition to the expected binary protein-ligand interactions, MZ1 forms 101 
additional protein-ligand interactions within the ternary complex. The PEG linker makes van 102 
der Waals interactions with the BC loop of Brd4BD2 and a hydrogen bond between the ether 103 
oxygen adjacent to the amide linkage to JQ1 and the BD2-specific residue His437 (Fig. 1d). 104 
The same hydrogen bond between His437 and a PEG oxygen is also observed in a recent 105 
crystal structure of Brd4BD2 bound to MT1, a bivalent BET inhibitor comprised of two JQ1 106 
moieties linked by a PEG unit in a similar fashion as in MZ1 (Supplementary Fig. 4) 21. 107 
VHL and Brd4BD2 come together to sandwich MZ1 against their respective binding surfaces, 108 
burying otherwise solvent-exposed regions of the JQ1 and VH032 ligands. Specifically, 109 
Ala384, Leu385 and Gly386 from the ZA loop of Brd4BD2 contact the –CH2–phenyl portion 110 
of VH032, whilst His110 and Tyr112 of β4 of VHL contact one of the two thiophene methyl 111 
groups and the para-chlorophenyl ring of JQ1 (Fig. 1b). In addition, MZ1 folds onto itself in 112 
such a way that its PEG linker is packed between the tert-butyl group of the VH032 moiety 113 
and the para-chlorophenyl ring of JQ1 (Fig. 1a,d). Throughout a 100 ns molecular dynamics 114 
simulation, favorable intermolecular contacts were observed from JQ1 atoms to VHL, from 115 
VH032 atoms to Brd4BD2, and from the PEG linker atoms to both VHL and Brd4BD2, as well 116 
as intramolecular contacts within MZ1 involving the PEG linker and the JQ1 and VH032 117 
moieties (Fig. 2a and Supplementary Fig. 5). The surface area further buried by the ligand 118 
folding within the bowl-shaped interface was 1,933 Å2, resulting in a total extended buried 119 
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surface area of 2,621 Å2 for the ternary complex (see Supplementary Table 2 for a 120 
comparison with cereblon:phthalimides:target ternary complexes 2,3).  121 
Isoform-specific cooperativity of ternary complexes. The extensive new contacts observed 122 
in the crystal structures suggested the possibility that isoform-specific PPIs could play a role 123 
in the “cooperativity” of the ternary complex equilibria 22,23. To assess the thermodynamics of 124 
PROTAC-induced complex formation with VHL and BET BDs, we employed isothermal 125 
titration calorimetry (ITC) in solution (Table 1 and Supplementary Fig. 6). To disentangle 126 
contributions from binary and ternary complex formation equilibria we performed reverse 127 
titrations i.e. protein in syringe and ligand in cell. This experimental strategy avoids the 128 
characteristic “hook effect” observed with increasing concentrations of PROTACs, as 129 
formation of binary complexes competes with and eventually surpasses formation of ternary 130 
ones 23. First, we titrated a solution of BET BD against MZ1, ensuring no excess unbound 131 
PROTAC compound would be present at the end of the titration. This was followed by a 132 
titration of VCB into the saturated MZ1:BD complex, forming the ternary VCB:MZ1:BD 133 
complex (Fig. 2b, right panel). Titration of VCB into MZ1 alone (Fig. 2b, left panel) was 134 
then performed and used as reference, allowing potential cooperativity of ternary complex 135 
formation to be accurately quantified. By definition, a ternary system is considered positively 136 
cooperative if interactions enhance formation of the ternary complex (α = ௄ౚ	(஻௜௡௔௥௬)௄ౚ	(்௘௥௡௔௥௬) > 1; 137 
ΔpKd = pKdT (ternary) – pKd (binary) >0). Conversely, a system is termed negatively 138 
cooperative when formation of the ternary complex is diminished (α < 1; ΔpKd < 0), for 139 
example because of repulsive interactions or steric hindrance between the two components in 140 
the ternary complex. Non-cooperative equilibria would instead show unchanged Kd for the 141 
two steps (α = 1; ΔpKd = 0), suggesting no interactions (Fig. 2c). With all BET BDs used, we 142 
observed significant positively cooperative ternary complex formation (see Table 1, and plots 143 
of ΔpKd in Fig. 2d). Strikingly, the strongest cooperativity was observed for Brd4BD2 (α = 144 
18), followed by Brd3BD2 (α = 11; Table 1 and Fig. 2d). The large cooperativity observed led 145 
to steep transition of the sigmoidal binding curve (Fig. 2b, right panel), suggesting that the 146 
fitted Kd value could potentially be underestimating the real binding affinity of this ternary 147 
complex.  All BD1s also exhibited positive cooperativity, albeit to a much lesser extent (α 148 
between 2 and 3). Brd4BD2 and Brd3BD2 not only exhibited the greatest cooperativity amongst 149 
all BET BDs, they also formed the most stable ternary complexes overall (ΔG (binary + 150 
ternary) = –22.2 ± 0.1 and 22.0 ± 0.2 kcal/mol, respectively), ~2 kcal/mol more stable than 151 
e.g. Brd2BD1 (ΔG = –20.3 ± 0.2 kcal/mol).  152 
To understand the impact of cooperativities of different BET BDs ternary complexes on their 153 
relative population, we applied a mathematical model of ternary equilibrium 23. We simulated 154 
the fraction of ternary complex formation for VCB, MZ1 and six individual BET BDs, using 155 
our measured binary Kds and cooperativities α (Table 1) and protein concentrations of 40 nM 156 
(to be around the Kd values and to match the concentrations used later in AlphaLISA). 157 
Overlay of simulations showed that the relative populations of each ternary complex vary 158 
significantly, with Brd4BD2 being the most populated, and, as an example, ~2.5 fold greater 159 
than Brd2BD1 at any given concentration of PROTAC (Fig. 2e). To interrogate this relative 160 
trend experimentally, we employed a proximity AlphaLISA assay that can achieve high 161 
signal amplification in response to formation of ternary complexes over an energy transfer 162 
distance of up to 200 nm 24,25. At every fixed component concentration, the relative trend 163 
observed in AlphaLISA signal was broadly consistent with the cooperativity trends measured 164 
by ITC, with Brd4BD2 and Brd3BD2 giving greater signal, while Brd2BD1 giving the lowest 165 
response (Fig. 2f). A similar trend was observed with the analogous MZ2 (PEG4), MZ3 166 
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(PEG3-Phe) and MZ4 (PEG2) (Supplementary Fig. 7a–h). Taken together the data are 167 
consistent with target-specific cooperativities and stabilities of ternary complexes impacting 168 
on the relative population of this key intermediate species. 169 
Specificity of MZ1-induced protein-protein interactions. To evaluate to what extent the 170 
cooperativity of ternary complex formation is dictated by surface complementarity between 171 
VHL and the Brd4BD2 bromodomain, we mutated semi-conserved or non-conserved 172 
bromodomain residues forming key induced PPI contacts, but not directly involved in 173 
binding of MZ1 (Fig. 3a and Supplementary Fig. 5). Inspection of sequence alignments 174 
(Fig. 3a) and the crystal structure (Fig. 3b) guided us to select residues Glu383 and Ala384 in 175 
Brd4BD2 (the most cooperative of bromodomains), for site directed mutagenesis. These 176 
residues are Val106 and Lys107 in the corresponding positions in Brd2BD1, one of the least 177 
cooperative BET domains. In addition, the MD simulation evidenced extensive movement of 178 
loop 7 of VHL (ref. 26) bringing it in close contact with Lys378 of Brd4BD2 (Supplementary 179 
Fig. 5b–d), which corresponds to Gln101 in Brd2BD1. Based on these considerations, triple 180 
mutant Brd4BD2 K378Q/E383V/A384K (named QVK for simplicity) was designed. The 181 
mutations would make the PPI surface of Brd4BD2 closer to that of Brd2BD1, albeit with the 182 
caveat of introducing an extra charge overall. Conversely, a triple mutant of Brd2BD1 was 183 
designed in which the corresponding residues are switched to those of Brd4BD2 184 
(Q101K/V106E/K107A, named KEA for simplicity). In ITC, the QVK mutant exhibited 185 
significantly weakened cooperative complex formation relative to Brd4BD2 wild-type (WT) (α 186 
= 4; Table 1 and ΔpKd = 0.64 ± 0.04, see plots in Fig. 3c). Conversely, the cooperativity of 187 
the KEA mutant increased relative to Brd2BD1 WT (α = 8; Table 1 and Fig. 3c). Crucially, 188 
these mutations did not affect the Kd of each domain for MZ1 (Table 1), suggesting that the 189 
switch of cooperativity is independent of binary target engagement and instead is dictated by 190 
the induced PPIs. Consistent with the cooperativity switch measured by ITC, QVK reduced 191 
ternary complex formation in AlphaLISA compared to WT, whereas KEA displayed the 192 
opposite effect  (Fig. 3d with MZ1 and Supplementary Fig. 7i with MZ2). Taken together 193 
these data validate the ternary complex structure in solution and elucidate how specific PPIs 194 
influence cooperative recruitment of two target proteins to each other by a bifunctional 195 
molecule.  196 
Structure-designed AT1 is highly selective Brd4 degrader. In chemical probe and drug 197 
development knowledge of ligand-bound structures can guide the design of next-generation 198 
compounds. We therefore sought to create new PROTACs based on our crystal structure that 199 
could exhibit enhanced target depletion selectivity in cells toward Brd4. We noted that the 200 
side chain of the key tert-Leu group of VH032 projected an attractive vector to link directly 201 
to the JQ1 moiety (Fig. 4a), which we hypothesized could better discriminate against the 202 
relative binding orientation observed in the crystal. We therefore replaced tert-Leu with 203 
penicillamine and synthesized 1 (AT1, Fig. 4b) and other analogues 2–6 (AT2–AT6) bearing 204 
thioether linkages of varying length to JQ1 (Supplementary Fig. 1 and Methods). The 205 
modified VHL ligand within AT1 retained binding to VHL (Kd 330 nM, Supplementary 206 
Table 3, and Supplementary Fig. 8), a less than two-fold loss of potency relative to VH032 207 
(ref. 14) but approximately five-fold less compared to MZ1. ITC data comparing binary and 208 
ternary complexes revealed Brd4BD2 as the BET bromodomain forming the most cooperative 209 
(α = 7; ΔpKd = 0.84 ± 0.07) and most stable (ΔG = –20.2 ± 0.2 kcal/mol) of all ternary 210 
complexes with AT1 (Fig. 4c, Supplementary Table 3, and Supplementary Fig.  8). The 211 
same trend of cooperativity observed for MZ1 and the QVK and KEA mutants relative to WT 212 
was also observed with AT1 (Fig. 4c, Supplementary Table 3), suggesting AT1 recruits 213 
VHL and Brd4BD2 in the same relative orientation as does MZ1. We consistently observed by 214 
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AlphaLISA preferential recruitment of Brd4BD2 over the other BDs by AT1–6 (Fig. 4d and 215 
Supplementary Fig. 9). We next tested the activity of the new structure-designed molecules 216 
to induce degradation of BET proteins in cells, and observed remarkable Brd4-selective 217 
depletion at all concentrations tested, with depletion of Brd4 after 24 h treatment with 1–3 218 
μM of AT1 and negligible activity against Brd2 and Brd3 (Fig. 4e, see Supplementary Fig. 219 
9 for AT2–6). Specificity for Brd4 degradation was not due to differences in protein synthesis 220 
rates, as shown by control treatments with cycloheximide, which blocks protein translation 221 
(Supplementary Fig. 10). To assess whether ubiquitination of lysine residues could play a 222 
role in the observed selectivity, we combined our EloBC–VHL–MZ1–Brd4BD2 complex with 223 
existing whole CRL structural information into a model of the entire CRL2VHL–MZ1–224 
bromodomain assembly (Supplementary Fig. 12a). Several lysine residues are surface 225 
exposed and accessible to the E2-Ub in this model at distances between 50–60 Å, consistent 226 
with known CRL substrates 27. Mapping MZ1-induced ubiquitination sites in vitro identified 227 
Lys346 on Brd4BD2 and several sites on the other BET-BDs (Supplementary Fig. 12b-d). 228 
Unbiased and quantitative isobaric tagging mass spectrometry proteomics confirmed Brd4 as 229 
the sole protein markedly depleted (to ~40%) upon treatment with AT1, amongst the 5,674 230 
detected proteins that passed filtering criteria (Fig. 4f and Supplementary Data Set 1). 231 
Crucially, no effect on protein levels of Brd2 and Brd3 was observed with AT1, in contrast 232 
with MZ1 that exerted a broader and more profound effect across all BET proteins, albeit still 233 
preferential toward Brd4 (Fig. 4g). Together these data qualify AT1 as a new highly selective 234 
degrader of Brd4 in cells. 235 
Discussion  236 
We put forth a model for how cooperative recruitment of a target close to an E3 ligase in a 237 
ternary complex by a PROTAC molecule can impact on the effectiveness and selectivity of 238 
target degradation (Fig. 5). Our work shines structural insights into how bifunctional 239 
molecules can induce target-specific interactions in the ‘enzyme-substrate’ ternary complex 240 
species key for PROTAC catalytic activity. These cooperative molecular recognition features 241 
contribute to how tightly and stably the ‘neo-substrate’ can be bound to the ligase, impacting 242 
on the relative population of the complex and consequently on the catalytic efficiency of the 243 
process. For homologous targets as is the case with BET bromodomains, we show how these 244 
features add a level of target depletion selectivity independently of binary target engagement.  245 
We illustrate the relevance of measuring cooperativities of ternary complex formation in 246 
solution using ITC. One of the main advantages of the assay set-up as described here is that it 247 
is designed to avoid issues associated with the hook effect. While the assay may be used to 248 
characterize in full a handful of compounds and systems, it requires large quantities of 249 
material and notably lacks throughput. Alternative bioassays to quantify formation of ternary 250 
complexes could circumvent this limitation, and we provide evidence that proximity 251 
AlphaLISA assay can be used for these purposes. However, AlphaLISA data should be 252 
interpreted with caution, even when comparing highly conserved domains as done here, 253 
because in this bead-based technology the multiplicity of binding sites and relative linkage 254 
and orientation of components immobilized to the beads may influence the measured signal 255 
24,28. Moreover, it can be difficult to deconvolute individual binding parameters from dose–256 
response curves monitoring ternary complex formation, because these are often bell–shaped 257 
curves complicated by the hook effect 23. We anticipate that future assay developments in this 258 
direction will help prioritize complexes for structural studies and to drive drug development 259 
programs. The results of our study are of particular relevance because VHL-based BET 260 
 7
degraders similar to the ones described here have proven to be bioavailable and active in vivo 261 
29 and could potentially enter clinical trials as early as 2017 (ref. 4). 262 
Our study points to the importance that the bifunctional molecule “folds in itself” in such a 263 
way that its two heads can recruit the respective targets into productive proximity. The result 264 
of this process is the burial of extensive surface area, the formation of new PPIs, contributing 265 
to the high stability and cooperativity of ternary complexes. Our work has therefore major 266 
implications for future PROTAC drug design, which has so far been somewhat empirical and 267 
has largely adopted a combinatorial “plug-and-play” strategy 11. The proposed model 268 
suggests that bifunctional molecules should be rationally designed and prioritized based on 269 
their ability to induce favorable contacts and allow forming a stable complex between the E3 270 
ligase and the target. While ligand-induced proximity is expected to strengthen potential PPIs 271 
because of the reduced entropic cost, we show that the level of surface complementarity 272 
between the two proteins in their relative orientation imposed by the bifunctional molecule 273 
dictates cooperative complexation. While the exact relative orientation between VHL and 274 
Brd4 observed in the crystal may not be the only one that the system can adopt in solution 275 
once free from potential constraints of crystal packing, our data suggests that it captures a 276 
significant species underlying MZ1 function. Maximizing the diversity of E3s recruited 30, 277 
and linking positions and vectors from the E3 and target ligands, will thus be important to 278 
achieve target-specific degraders. 279 
In an example of first layer of this rational design, we show how new PROTACs designed 280 
based on our ternary structure can lead to enhanced selectivity of depletion in cells for the 281 
crystallized target Brd4. The efficiency and selectivity of cellular protein knockdown will 282 
inevitably depend on other factors, including compound permeability and stability, the 283 
expression level of the hijacked CRL and its relative activity and flexibility 27,31, as well as 284 
target abundance and re-synthesis rates. Differing ubiquitination rates could also in principle 285 
influence target degradation selectivity. To this end, in addition to increasing their relative 286 
population, cooperative and stable complexes would be expected to exhibit slower 287 
dissociation rates and longer half-lives, potentially aiding the efficiency of target 288 
ubiquitination by the hijacked ligase. Differing availability and access of surface lysine 289 
residues between alternate substrates could also play a role. However, based on our data, the 290 
presence of many surface Lys on BET-BDs, and the flexibility and large ubiquitination zone 291 
of CRLs 2,27, we view it unlikely that target ubiquitination plays a role in the observed 292 
selectivity of Brd4 degradation. Obtaining a more detailed biochemical picture of target 293 
ubiquitination in a cellular context will be of clear importance for future investigation. 294 
For targeted protein degradation, converting a pan-selective or promiscuous probe ligand into 295 
a more selective degrader probe provides new opportunities to improve target validation and 296 
could minimize off-target effects. In addition to dictate selectivity of target degradation, 297 
highly cooperative ternary E3:PROTAC:target systems would be anticipated to unlock the 298 
possibility to effectively degrade hitherto “undruggable” targets using ligands with inherently 299 
weak binary binding affinities. A more general implication of this study is the feasibility to 300 
induce de novo protein-protein interactions, or stabilize weakened ones, using bifunctional 301 
small molecules, a feature previously established with mono-functional ‘molecular glues’ 32 302 
such as the plant hormones auxin 33 and jasmonate 34, the phthalimide immunomodulatory 303 
drugs (IMiDs) 2,3,31,35-38, and macrocyclic natural products such as rapamycin and 304 
cyclosporine 39,40. We envision that extensions of PPI-stabilizing capabilities to hetero- or 305 
homo-bifunctional small molecules 21,41,42 beyond PROTACs as highlighted here could 306 
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expand the target spectrum accessible to PPI stabilizers, and provide a new paradigm of 307 
selective chemical intervention for structural chemical biology and drug discovery. 308 
 309 
METHODS 310 
Methods and any associated references are available in the online version of the paper. 311 
Accession codes 312 
Atomic coordinates and structure factors for hsBrd4BD2–MZ1–hsVHL–hsEloC–hsEloB have 313 
been deposited in the Protein Data Bank (PDB) under accession number 5T35.  314 
 315 
Data availability 316 
Any supplementary information, chemical compound information and source data are 317 
available in the online version of the paper. Correspondence and requests for materials should 318 
be addressed to A.C. (a.ciulli@dundee.ac.uk). 319 
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Figure Legends  441 
Figure 1. The crystal structure of the Brd4BD2:MZ1:VHL-ElonginC-ElonginB complex. a, 442 
Overall structure of Brd4BD2:MZ1:VHL-ElonginC-ElonginB in ribbon representation. Top middle, 443 
chemical structure of bifunctional PROTAC molecule MZ1. Top right, Fo−Fc omit map generated 444 
prior to ligand modelling contoured at 3.0σ around bound MZ1. b, Key residues forming the 445 
hydrophobic "base" of the induced Brd4BD2:VHL interface. The "WPF" shelf of Brd4BD2 and extended 446 
"PWPF" stack are outlined in black. The JQ1 and VH032 elements of MZ1 are labelled in yellow. c, 447 
Electrostatic potential map showing the charged zipper contacts between Brd4BD2 residues D381 and 448 
E383 with VHL residues R107 and R108. d, Electrostatic potential map showing the interaction 449 
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between Brd4BD2 residue E438 with VHL residue R69. The hydrogen bond between H437 of Brd4BD2 450 
and the PEG linker of MZ1 is also shown. Dashed lines indicate hydrogen bonds with shown distance 451 
in angstroms (Å). 452 
 453 
Figure 2. Brd4BD2 and VHL form a stable, cooperative complex in the presence of MZ1. a, Novel 454 
ligand contacts are induced by ternary complex formation. Colour strength (from white to red) 455 
indicates the mean enthalpic energies of individual MZ1 atoms in contacting Brd4BD2 (left) or VHL 456 
(right), as well as intra-ligand contacts within MZ1 (centre) in a 100 ns MD simulation. b, Inverse 457 
ITC titrations of VCB into MZ1 (left, representative of eight replicates) and VCB into the pre-formed 458 
MZ1:Brd4BD2 (right, performed in duplicate) c, Ternary complex equilibria and definition of 459 
cooperativities. d, ΔpKd measured for VCB with MZ1 and the indicated BET-BDs, reported as 460 
difference (± uncertainty), from pKd values measured as mean (± 1 s.e.m.) as described in Online 461 
Methods. Statistical significance of pKd values for ternary titrations compared to the corresponding 462 
binary titrations was assessed by two-tailed t-test assuming equal variances, and is indicated as * (p-463 
value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). e, Simulated fraction of ternary 464 
complexes based on mathematical model described in ref. 23. f, AlphaLISA intensity values titrating 465 
VCB against BET-BDs with MZ1. AlphaLISA intensities represent mean (± 1 s.d.) of intensity values 466 
from four technical replicates. The hook effect observed on these curves is due to biotinylated-VCB 467 
oversaturating the donor beads, resulting in a progressive decrease in signal. 468 
 469 
Figure 3. The molecular basis of MZ1-induced compact complex formation between Brd4BD2 470 
and VHL. a, Sequence alignment of BET bromodomains. Residues of Brd4BD2 in contact with MZ1 471 
and/or VHL are highlighted. b, Structural alignment of Brd2BD1 (yellow) superposed on Brd4BD2 (dark 472 
green) in the ternary structure with MZ1 and VHL. Key, non-conserved interacting residues are 473 
shown in sticks. c, ΔpKd measured for VCB with MZ1 and the indicated BET-BDs, reported as 474 
difference (± uncertainty), from pKd values measured as mean (± 1 s.e.m.) as described in Online 475 
Methods. Statistical significance of pKd values for ternary titrations compared to the corresponding 476 
binary titrations (in black) and for ternary titrations of WT compared to the corresponding triple-477 
mutant (in red) was assessed by two-tailed t-test assuming equal variances, and is indicated as * (p-478 
value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). d, AlphaLISA intensity values titrating 479 
Brd2BD1, Brd4BD2 and corresponding mutants against VCB with MZ1. AlphaLISA intensities are the 480 
mean (± 1 s.d.) of intensity values from four technical replicates. 481 
 482 
Figure 4. Structure-guided design and characterization of Brd4-selective degrader AT1. a, A 483 
vector linking VH032 to JQ1 that maintains the relative binding orientation. b, Chemical structure of 484 
AT1. c, ΔpKd measured for VCB with AT1 and the indicated BET-BDs, reported as difference (± 485 
uncertainty), from pKd values measured as mean (± 1 s.e.m.). Statistical significance of pKd values for 486 
ternary titrations compared to corresponding binary (black) and for ternary WT compared to 487 
corresponding mutant (red) was assessed by two-tailed t-test assuming equal variances. d, AlphaLISA 488 
intensity values titrating VCB against BET-BDs with AT1 (left) and BET-BDs against VCB with 489 
AT1 (right). AlphaLISA intensities are the mean (± 1 s.d.) of intensity values from four technical 490 
replicates. e–g, Highly selective degradation of Brd4 by AT1 in HeLa cells after 24 h. e, Protein levels 491 
are shown from one representative of three biological replicates, visualized by immunoblot (left) and 492 
quantified relative to DMSO (right). Intensity values were measured as described in Online Methods. 493 
Full gels are provided in Supplementary Fig. 11. f, Impact of AT1 (1 µM, 24 h) on the cellular 494 
proteome. Data plotted as fold change (log2) of replicate 1 vs replicate 2, for a total of 5,674 proteins 495 
quantified (see Online Methods). g, Quantified levels of BET proteins shown are mean (± 1 s.e.m.) 496 
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from two replicates relative to mean of vehicle. Statistical significance of relative protein abundance 497 
compared to DMSO was assessed by two-tailed t-test assuming equal variances. Statistical 498 
significance indicated as * (p-value < 0.05), ** (p-value < 0.01) or *** (p-value < 0.001). 499 
 500 
Figure 5. Schematic model of selective PROTAC-induced target degradation. A target is 501 
preferentially recruited in a stable and positively cooperative ternary complex with the E3 ubiquitin 502 




Table 1. Thermodynamic parameters of formation of binary and ternary complexes between MZ1, VCB and BET 506 
bromodomains measured by isothermal titration calorimetry. 507 
Protein in 
syringe 
Species in cell Kd (nM) 
ΔG (kcal × mol-
1) ΔH (kcal × mol
-1) –TΔS (kcal 
× mol-1) N  α ΔpKd 
Brd2BD1 
MZ1 
62 ± 6 –9.84 ± 0.06 –12.8 ± 0.7 3.0 ± 0.8 1.1 ± 0.1   
Brd2BD2 60 ± 3 –9.85 ± 0.03 –9.8 ± 0.3 –0.1 ± 0.3 1.2 ± 0.1   
Brd3BD1 21 ± 5 –10.2 ± 0.1 –14.7 ± 0.8 4.2 ± 0.9 1.1 ± 0.1   
Brd3BD2 13 ± 3 –10.8 ± 0.1 –14.0 ± 0.9 3.3 ± 0.7 1.05 ± 0.02   
Brd4BD1 39 ± 9 –10.1 ± 0.1 –14.7 ± 0.4 4.6 ± 0.5 0.95 ± 0.03   
Brd4BD2 15 ± 1 –10.68 ± 0.04 –10.9 ± 0.4 0.2 ± 0.4 1.08 ± 0.07   
Brd2BD1 
KEA 
69 ± 9 –9.78 ± 0.08 –14 ± 1 4 ± 1 0.83 ± 0.08   
Brd4BD2 
QVK 
22 ± 8 –10.5 ± 0.2 –12.4 ± 0.5 1.9 ± 0.2 1.0 ± 0.1   
VCBa MZ1a 66 ± 6 –9.81 ± 0.05 –7.7 ± 0.3 –2.1 ± 0.3 0.93 ± 0.04   
VCB 
MZ1:Brd2BD1 24 ± 8 –10.4 ± 0.2 –7.3 ± 0.2 –3.1 ± 0.4 1.1 ± 0.2 2.9 0.4 ± 0.2 
MZ1:Brd2BD2 28 ± 3 –10.3 ± 0.1 –10.5 ± 0.1 0.2 ± 0.2 1.07 ± 0.02 2.3 0.36 ± 0.06
MZ1:Brd3BD1 19 ± 4 –10.6 ± 0.1 –8.8 ± 0.5 –1.8 ± 0.7 1.01 ± 0.01 3.5 0.5 ± 0.1 
MZ1:Brd3BD2 7 ± 2 –11.2 ± 0.2 –6.3 ± 0.1 –4.9 ± 0.3 0.99 ± 0.04 10.7 1.0 ± 0.2 
MZ1:Brd4BD1 28 ± 6 –10.3 ± 0.1 –9.1 ± 0.9 –1 ± 1 0.97 ± 0.06 2.3 0.4 ± 0.1 
MZ1:Brd4BD2 3.7 ± 0.7 –11.5 ± 0.1 –8.9 ± 0.1 –2.6 ± 0.2 1.02 ± 0.02 17.6 1.24 ± 0.09
MZ1:Brd2BD1 KEA 12 ± 7 –10.9 ± 0.4 –5.7 ± 0.2 –5.2 ± 0.2 0.8 ± 0.1 7.9 0.8 ± 0.3 
MZ1:Brd4BD2 QVK 14.9 ± 0.1 –10.68 ± 0.03 –6.2 ± 0.3 –4.5 ± 0.3 0.9 ± 0.1 4.2 0.62 ± 0.04
 508 
All ITC titrations were performed at 25 °C. Values reported are the mean ± S.E.M. from two independent measurements, except for 509 
VCB titration into MZ1 (line a) for which values reported are the mean ± S.E.M. from eight independent measurements. 510 
 511 
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Online Methods 512 
 513 
Chemical synthesis: Synthesis of compounds described in this paper and their intermediates 514 
are described in the Supplementary Note.  515 
Constructs, protein expression and purification. Wild-type and mutant versions of human 516 
proteins VHL (UniProt accession number: P40337), ElonginC (Q15369), ElonginB 517 
(Q15370), Brd2 (P25440), Brd3 (Q15059) and Brd4 (O60885) were used for all protein 518 
expression. For expression of VBC, N-terminally His6-tagged VHL (54–213), ElonginC (17–519 
112) and ElonginB (1–104) were co-expressed in Escherichia coli BL21(DE3) at 24 °C for 520 
16 h using 3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). E. coli cells were lysed 521 
using a pressure cell homogenizer (Stansted Fluid Power) and lysate clarified by 522 
centrifugation. His6-tagged VCB was purified on a HisTrapFF affinity column (GE 523 
Healthcare) by elution with an imidazole gradient. The His6 tag was removed using TEV 524 
protease and the untagged complex dialysed into low concentration imidazole buffer. VCB 525 
was then flowed through the HisTrapFF column a second time, allowing impurities to bind as 526 
the complex eluted without binding. VCB was then additionally purified by anion exchange 527 
and size-exclusion chromatography using MonoQ and Superdex-75 columns (GE 528 
Healthcare), respectively. The final purified complex was stored in 20 mM Bis Tris, pH 7, 529 
150 mM sodium chloride and 1 mM dithiothreitol (DTT). Brd2BD1 (71–194), Brd2BD2 (344–530 
455), Brd3BD1 (24–146), Brd3BD2 (306–416), Brd4BD1 (44–178) and Brd4BD2 (333–460) as 531 
well as equivalent mutant constructs were expressed with an N-terminal His6 tag in E. coli 532 
BL21(DE3) at 18 °C for 20 h using 0.2 mM IPTG. His6-tagged BDs were purified on nickel 533 
Sepharose™ 6 fast flow beads (GE Healthcare) by elution with increasing concentrations of 534 
imidazole. For crystallography the His6-tagged BD was cleaved with TEV protease and 535 
dialysed into low concentration imidazole buffer. The BD was then flowed over the nickel 536 
beads a second time to remove impurities and protease. BDs were then additionally purified 537 
by size-exclusion chromatography using a Superdex-75 column. For AlphaLISA, ITC and 538 
ubiquitination reactions, following elution of His6-tagged BDs from the nickel beads, the BDs 539 
were purified by size-exclusion chromatography using a Superdex-75 column. The final 540 
purified proteins were stored in 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 541 
(HEPES), pH 7.5, 150 mM sodium chloride and 1 mM DTT. All chromatography 542 
purification steps were performed using Äkta FPLC purification systems (GE Healthcare) or 543 
glass econo-columns (Bio-Rad) at room temperature. 544 
Crystallography. VCB, MZ1 and Brd4BD2 were mixed as a 1:1:1 stoichiometric ternary 545 
complex with a final concentration of 10 mg/mL. Drops of the ternary complex were mixed 546 
1:1 with 13% (w/v) PEG 8000 and 0.1 M sodium citrate (pH 6.3) in the hanging-drop vapour 547 
diffusion format. Crystals appeared within minutes and were fully grown after one day. A 548 
crystal was dehydrated in a solution containing 18% (w/v) PEG 8000 for a few minutes and 549 
flash-cooled in liquid nitrogen using 20% 2-methyl-2,4-pentanediol in liquor solution as a 550 
cryoprotectant. Diffraction data were collected at Diamond Light Source beamline I04-1 551 
using a Pilatus 6M-F detector at a wavelength of 0.92819 Å. Indexing and integration of 552 
reflections was performed using XDS with the XDSGUI interface43, and scaling and merging 553 
with AIMLESS44 in CCP4i45.  The Wilson B factor was estimated at 47.2 Å2. To solve the 554 
phase problem the molecular replacement method was used with the program PHASER46 555 
using search models derived from the coordinates of VCB (PDB entry 1VCB26) and Brd4BD2 556 
(PDB entry 2OUO20). Two instances of the ternary complex were found in the asymmetric 557 
unit, indicating a final solvent content of 68% as calculated from the Matthews coefficient. 558 
The initial model was refined iteratively using REFMAC47 and COOT48. Ligand structures 559 
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and restraints were generated using the PRODRG server49. The MOLPROBITY server50 was 560 
used to validate the geometry and steric clashes in the structures; the distribution of backbone 561 
torsion angles in the Ramachandran plot are 98.3% in the favored region and 1.7% in the 562 
allowed region. The structure has been deposited in the protein data bank (PDB) with 563 
accession code 5T35 and data collection and refinement statistics are presented in 564 
Supplementary Table 1. Interfaces and contacts observed in the crystal structure were 565 
calculated with PISA51 and LIGPLOT52. All figures were generated using PyMOL. 566 
Molecular dynamics simulations. MD simulations were carried out using the NAMD 567 
program53 and the CHARMM 36 force field54. We attempted to derive ab initio topology and 568 
parameter files for MZ1 using Jaguar v. 9.0 (Schrödinger Inc., LLC, New York, NY, US). 569 
However, characterization of the minimized structure as a minimum by vibrational analysis 570 
proved unsuccessful (number of imaginary frequencies > 0) using several approaches and 571 
initial structures, probably due to the large number of atoms. Therefore topology and 572 
parameter files were generated using the CGenFF server55.  573 
To simulate the Brd4BD2:MZ1:VHL ternary complex in solution, the coordinates of the X-ray 574 
crystal structure of the complex (chains A and D) were used as starting structure for 575 
simulation. ElonginB and ElonginC, which are sufficiently far from the hydroxyproline 576 
recognition site of VHL (> 20 Å), were excluded to increase computational efficiency 577 
throughout the simulation. The model was solvated in a TIP3P water box with a padding of 578 
12 Å from the edge of the box to any protein atom. The system charges were neutralized with 579 
sodium or chloride ions as appropriate. The solvated system was minimized for 3,000 steps 580 
with all protein and MZ1 atoms restrained to eliminate residual unfavorable interactions 581 
between each other and the solvent, followed by another 5,000 steps with all atoms free to 582 
move. Heating of the system from 0 to 300 K was achieved in 100 ps (time step of 1 fs), with 583 
fixed protein backbone atoms to allow relaxation of the solvent. The system was 584 
subsequently equilibrated for 600 ps (time step of 2 fs) with all atoms free to move. The NPT 585 
ensemble was used during production simulation of 100 ns (time step of 2 fs). The 586 
temperature was controlled with a Langevin thermostat at 300 K, and the pressure with a 587 
Nose-Hoover Langevin piston barostat at 1 bar. A SHAKE constraint was applied to all 588 
bonds containing hydrogen atoms. Short-range nonbonded interactions were switched at 10 Å 589 
and cut off at 12 Å, and particle mesh Ewald summation was employed for long-range non-590 
bonded interactions.  591 
The trajectory was analysed using VMD v. 1.9.256 and taking snapshots every 10 ps of 592 
simulation, unless otherwise stated. To calculate root-mean-square deviations (RMSD) 593 
throughout the simulation, ternary complexes were superposed to the crystallographic 594 
complex using an in-house PyMOL script considering only Cα atoms of the VHL protein 595 
within a shell of 10 Å from MZ1. This was implemented in order to diminish the effect of 596 
structural rearrangements occurring far from the hydroxyproline recognition site of VHL 597 
during the simulation arising from the absence of ElonginB and ElonginC. Radius of gyration 598 
(Rg) of the ternary complex, i.e. the radius of a sphere with equivalent moment of inertia, was 599 
computed using Carma57 at each snapshot considering the protein backbone. Buried surface 600 
area (BSA) upon complex formation, i.e. the difference in surface-accessible surface area 601 
(SASA) between the formed complex and the unbound partners in the system, was computed 602 
considering all protein atoms and a spherical probe of radius 1.4 Å. Intermolecular contacts, 603 
i.e. pair-to-pair contacts between an amino acid in Brd4BD2 and VHL, were considered 604 
formed if more than five atoms of the amino acid were at a distance closer than 4.0 Å from 605 
the partner protein. Intermolecular contacts were computed using the Timeline plugin v. 2.3 606 
as implemented in VMD. Per-residue and per-atom inter- and intramolecular interaction 607 
energies (EvdW + electrostatic) were computed using an in-house automated routine of the NAMD 608 
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Energy plugin v. 1.4 as implemented in VMD. Interaction energies were estimated by adding 609 
the pair-wise van der Waals and electrostatic contributions between individual amino acids or 610 
atoms and the corresponding partner. In the case of per-atom calculations, the interaction 611 
energies of hydrogen atoms were added to their corresponding heavy atom. For 612 
intramolecular interactions analysis, MZ1 was divided into three sections (JQ1, PEG linker, 613 
and VH032) and pair-wise energetic contributions from the atoms of each section to the rest 614 
of the molecule (excluding 1–4 bonded atoms) were calculated. In order to obtain comparable 615 
and interpretable results, the following scaling factor and cutoff value were applied to the 616 
electrostatic contribution: 617 
൜if |EvdW|≥ 0.1: Eelectrostatic = 0.07*Eraw electrostatics if |EvdW| < 0.1: Eelectrostatic = 0  
Isothermal titration calorimetry (ITC) Titrations were performed on an ITC200 micro-618 
calorimeter (GE Healthcare). The titrations were all performed as reverse mode (protein in 619 
syringe, ligand in cell) and consisted of 19 injections of 2 µL protein solution (20 mM Bis-620 
tris propane, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 0.02 % DMSO, 621 
pH 7.4 ) at a rate of 2 sec/µL at 120 s time intervals. An initial injection of protein (0.4 µL) 622 
was made and discarded during data analysis. All experiments were performed at 25 ºC, 623 
whilst stirring at 600 rpm. PROTACs (MZ1 or AT1) were diluted from a 10 mM DMSO 624 
stock solution to 20 µM in buffer containing 20 mM Bis-tris propane, 150 mM NaCl, 1 mM 625 
tris(2-carboxyethyl)phosphine (TCEP), pH 7.4. The final DMSO concentration was 0.01 or 626 
0.02 %. Bromodomain (100 or 200 µM, in the syringe) was titrated into the PROTAC (10 or 627 
20 µM, in the cell). At the end of the titration, the excess of solution was removed from the 628 
cell, the syringe was washed and dried, VCB complex (84 or 168 µM, in the same buffer) 629 
was loaded in the syringe and titrated into the complex PROTAC:bromodomain. The 630 
concentration of the complex in the cell (C) after the first titration (8.4 or 16.8 µM), was 631 
calculated as follow:  632 
ܥ = 	 ܥ଴ ∙ ௖ܸ௘௟௟
௖ܸ௘௟௟ + ௜ܸ௡௝ 
where: C0 is the initial concentration of the PROTAC in the cell (20 µM), Vcell is the volume 633 
of the sample cell (200.12 µL) and Vinj is the volume of titrant injected during the first 634 
titration (38.4  µL). Titrations for the binary complex PROTAC:VCB were performed as 635 
follow: to the solution of PROTAC (10 or 20 µM, in the cell), buffer (38.4 µL) was added by 636 
means of a single ITC injection. The excess of solution was removed from the cell, the 637 
syringe was washed and dried, VCB complex (84 or 168 µM, in the same buffer) was loaded 638 
in the syringe and titrated into the diluted PROTAC solution. The data were fitted to a single 639 
binding site model to obtain the stoichiometry n, the dissociation constant Kd and the 640 
enthalpy of binding ΔH using the Microcal LLC ITC200 Origin software provided by the 641 
manufacturer. The reported values are the mean ± s.e.m. from independent measurements 642 
(eight for VCB into MZ1; seven for VCB into AT1; two for each BD into VCB:PROTAC). 643 
Simulations of ternary complex fractions. Fractions of ternary complexes were calculated 644 
by applying the ternary equilibria model in the excel spreadsheet provided in ref. 23. Input 645 
parameters were [VHL]t = [BD]t = 40 nM; Kd (VHL) = 66 nM; Kd and α (BD) were as 646 
measured by ITC (Table 1). 647 
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Biotinylation of VCB. To biotinylate VCB the complex was mixed in a 1:1 stoichiometry 648 
with EZ-Link NHS-PEG4-Biotin (Thermo Scientific) and incubated at room temperature for 649 
1 h. To remove any unreacted NHS-biotin the sample was run over a PD-10 desalting column 650 
(GE Healthcare) into 20 mM HEPES, pH 7.5, 150 mM sodium chloride and 1 mM DTT. 651 
AlphaLISA assays. All assays were performed at room temperature and plates sealed with 652 
transparent film between addition of reagents. All reagents were diluted in 50 mM HEPES, 653 
pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine serum albumin and 0.02% (w/v) 3-[(3-654 
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and each solution was 655 
prepared as a 5× stock and mixed into a final volume of 25 μL per well. Each protein sample 656 
(biotinylated VCB and His6-BD) and PROTAC were mixed and incubated for 1 h. Ni-coated 657 
acceptor beads were added and plates incubated another 1 h. Streptavidin-coated donor beads 658 
were added and plates incubated for a final 1 h. Plates were read on a PHERAstar FS (BMG 659 
Labtech) using an optic module with an excitation wavelength of 680 nm and emission 660 
wavelength of 615 nm. Within each read there was a settling time of 0.1 s, an excitation time 661 
of 0.3 s and an integration time of 0.6 s. For BET-BD titration experiments, VCB and 662 
PROTACs or Biotin-JQ1 alone were kept constant at a final concentration of 20 nM and 663 
His6-BD was serially diluted three-in-five from 200 nM. For VCB/Biotin-JQ1 titration 664 
experiments, His6-BDs and PROTACs were kept constant at a final concentration of 40 nM 665 
and VCB or Biotin-JQ1 was serially diluted one-in-two from 200 nM. The intensity values 666 
were plotted with concentration values on a log10 scale.  667 
Tissue culture. Human HeLa cell lines were obtained from ATCC and were kept in DMEM 668 
medium (Gibco) supplemented with 10% FBS (Gibco), L-glutamate (Gibco), penicillin and 669 
streptomycin. Cells were kept in incubator at 37 °C, 5% CO2. All cell lines were tested for 670 
mycoplasma contamination every month using MycoAlert™Mycoplasma detection kit 671 
(Lonza). 672 
Cell treatment and lysis. HeLa cells were seeded at 2.5×105 per well on a standard six-well 673 
plate. After a day, cells were treated with test compounds for the desired period of time. Cells 674 
were washed with PBS twice before lysis. Lysis was achieved by applying RIPA buffer 675 
(Sigma), supplemented with 1× protease inhibitor cocktail (Roche), Benzonase (Merck) and 676 
0.5 mM MgCl2 to the cells on ice. Lysate was briefly sonicated and then centrifuged at 677 
20,000 × g for 10 min at 4 °C. Supernatant was collected as cell extract and protein 678 
concentration was measured by BCA assay. The extract was snap frozen in liquid nitrogen 679 
for storage before being used for Western blot analysis. Cycloheximide (C7698, Sigma 680 
Aldrich) was used at 100 µg/mL for the indicated times. 681 
Western blot. Blots were probed with antibodies for Brd4 (AbCam ab128874, 1:1,000 682 
dilution), Brd3 (AbCam ab50818, 1:500 dilution), Brd2 (AbCam ab139690, 1:2,000 683 
dilution), β-actin (AbCam ab8227, 1:2,000 dilution) and cMyc (AbCam ab32072, 1:1,000 684 
dilution) antibodies. Blots were developed with anti-Mouse or anti-Rabbit IRDye® 800CW 685 
secondary antibody from Licor (1:10,000 dilution) and bands visualized using Licor Odyssey 686 
Sa imaging system. Image processing and band intensity quantification were done using 687 
Licor Image Studio software Version 5.2.5. Ubiquitination blots were probed with anti-6×His 688 
antibody (AbCam ab18184, 1:2,000 dilution) and then with Anti-mouse IgG, HRP-linked 689 
Antibody (Cell Signaling technology #7076, 1:2,000 dilution). Probed blots were visualised 690 
with ECL Western Blotting Substrate (Pierce #32106) on film. 691 
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Sample preparation for MS proteomics. HeLa cells were seeded at 2×106 on a 100mm 692 
plate 24 h before treatment. To treat the cells, culture medium was replaced with 12 mL of 693 
medium containing the test compound. After 24 h, medium was removed and cells were 694 
washed with 12 mL of cold PBS twice. Samples were kept on ice from this point onwards. 695 
Cells were lysed in 0.5 mL of 100 mM Tris pH 8.0, 4% (w/v) SDS supplemented with 696 
protease inhibitor cocktail (Roche). The lysate was pulse sonicated briefly and then 697 
centrifuged at 17,000 × g for 15 min at 4 °C. The supernatant fraction of cell extract was 698 
snap-frozen in liquid nitrogen and stored in −80 °C freezer before further processing. 699 
Sample preparation for MS proteomics. Samples were quantified using a micro BCA 700 
protein assay kit (Thermo Fisher Scientific) and 200μg of each sample was processed and 701 
digested using the Filter Aided Sample Preparation (FASP) method 58. The samples were then 702 
desalted using a 7 mm, 3 ml C18 SPE cartridge column (EmporeTM, 3M) and labelled with 703 
TMT 59 10plexTM Isobaric Label Reagent Set (Thermo Fisher Scientific) as per manufacturers 704 
instructions. After labelling, the peptides from the 10 samples were pooled together in equal 705 
proportion. The pooled sample was fractionated into 20 discrete fractions using high pH 706 
reverse phase chromatography 60 on a XBridge peptide BEH column (130 Å, 3.5 µm 2.1 X 707 
150 mm, Waters) using an Ultimate 3000 HPLC system (Thermo Scientific/Dionex). Column 708 
temperature was set to 20 oC. The peptides were separated using a mix of buffers A (10 mM 709 
ammonium formate in water, pH 10) and B (10 mM ammonium formate in 90% CH3CN, pH 710 
10). The peptides were eluted from the column using a flow rate of 200 µl/min and a linear 711 
gradient from 5% to 60% buffer B over 60 min.  The peptides eluted from the column were 712 
separated into 40 fractions prior to concatenation into 20 fractions based on the UV signal of 713 
each fraction. All the fractions were dried in a speedvac concentrator and resuspended in 10 714 
µl 5% formic acid, then diluted to 1% prior to MS analysis. 715 
nLC-MS/MS analysis. The fractions were analysed sequentially on a Q ExactiveTM HF 716 
Hybrid Quadrupole-OrbitrapTM Mass Spectrometer (Thermo Scientific) coupled to an 717 
Ultimate 3000 RSLC nano UHPLC system (Thermo Scientific) and Easyspray column (75 718 
μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å, Thermo Scientific). The peptides 719 
from each fraction were separated using a mix of buffer A (0.1% formic acid in MS grade 720 
water) and B (0.08% formic acid in 80% MS grade CH3CN). The peptides from each fraction 721 
were eluted from the column using a flow rate of 300 nl/min and a linear gradient from 5% to 722 
40% buffer B over 122 min. The column temperature was set at 50 oC. The Q ExactiveTM HF 723 
Hybrid Quadrupole-OrbitrapTM Mass Spectrometer was operated in data dependent mode 724 
with a single MS survey scan followed by 10 sequential m/z dependant MS2 scans. The 10 725 
most intense precursor ions were sequencially fragmented by Higher energy Collision 726 
Dissociation (HCD). The MS1 isolation window was set to 0.4 Da and the resolution set 727 
120,000. MS2 resolution was set as 60,000. The maximum ion injection time for MS1 and 728 
MS2 were set at 50 msec and 200 msec, respectively. 729 
Peptide and protein identification. The raw ms data files for all 20 fractions were merged 730 
and searched against the Sprot database with taxonomy set to Homo sapiens by Proteome 731 
Discoverer Version 1.4 (Thermo Scientific) using the Mascot v.2.4.1 (Matrix Science) search 732 
engine for protein identification and TMT reporter ion quantitation. The identification was 733 
based on the following database search criteria: enzyme used Trypsin/P; maximum number of 734 
missed cleavages equal to 2; precursor mass tolerance equal to 10 ppm; fragment mass 735 
tolerance equal to 0.06 Da; dynamic modifications: Oxidation (M), Dioxidation (M), Acetyl 736 
(N-term), Gln->pyro-Glu (N-term Q), Pro->Hyp (P), Deamidation(N,Q); static modifications: 737 
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Carbamidomethyl (C), TMT10plex (K), TMT10plex (N-term). For protein identification the 738 
mascot ion score threshold was set at 30 and a minimum of 2 peptides was required. 739 
Peptide and protein quantitation. The ratios of TMT reporter ion abundances in MS/MS 740 
spectra generated by HCD from raw data sets were used for TMT quantification. Isotopic 741 
correction factors were applied for the batch of TMT reagents used in this experiment as per 742 
manufacturers recommendation. A minimum of two unique peptides was used for 743 
quantitation and the resultant ratios were normalized based on protein median. Quantified 744 
proteins were filtered if the absolute fold change difference between the two DMSO 745 
replicates was ≥ 1.3. 746 
Model construction of the multisubunit CRL2VHL–MZ1–Brd4 complex. A structural 747 
model of the CRL2VHL (VHL–EloC–EloB–Cul2–Rbx1) with bound MZ1–Brd4BD2 at one end 748 
and E2–Ubiquitin at the other end was constructed in PyMOL by aligning our Brd4BD2–749 
MZ1–VHL–EloC–EloB on to the quaternary structure VHL–EloC–EloB–Cul2NTD (PDB 750 
entry 4WQO). Cul2NTD and Cul2CTD were modelled based on the structures of Cul5NTD (PDB 751 
entry 2WZK) and Cul1CTD–Rbx1 (PDB entry 3RTR) and superposed onto full-length Cul1 752 
from PDB entry 1LDK. Finally, the Rbx1–E2–Ub arm was modelled based on the crystal 753 
structure of Rbx1–Ubc12~NEDD8–Cul1–Dcn1 (PDB entry 4P5O) superposed via the cullin 754 
subunit. 755 
Recombinant ubiquitination experiments and ubiquitination site identification. His6-756 
tagged BET-BDs (2 µM) were ubiquitinated in the presence of E1 Ube1 (19 nM), E2 Ube2d1 757 
(145 nM), ubiquitin (Ubiquigent, 1 mg/mL), recombinant VHL-ElonginC-ElonginB-Cullin2-758 
Rbx1 complex (330 nM) and MZ1 (2 µM) standing for 24 h at room temperature in a buffer 759 
of 25 mM HEPES, pH 7.5, 5 mM MgCl2, 100 mM NaCl, 2 mM ATP, 0.1 mg/mL BSA and 1 760 
mM TCEP. Reactions were terminated by the addition of 1× NuPAGE LDS sample buffer 761 
(Invitrogen).  762 
Sample preparation for MS. Samples were run 1–2 cm into a pre-cast 4–12% Bis-Tris 763 
NuPAGE gel and the entire protein content of each lane excised, washed and dried. Proteins 764 
were reduced with 10 mM DTT and 20 mM ammonium carbonate at 56 °C for 60 min and 765 
then alkylated with 50 mM N-ethylmaleimide and 20 mM ammonium carbonate at room 766 
temperature for 30 min. Proteins were trypsinized overnight at 30 °C and the resulting 767 
peptides extracted and dried down.  768 
nLC-MS/MS analysis. Each peptide sample was reconstituted in 10 µl 5% formic acid then 769 
diluted to 1% prior to MS analysis. Peptide samples were injected onto a C18 PepMap 100 770 
(300 µm x 5 mm, Thermo Scientific) trap column with buffer A (0.1% formic acid in MS 771 
grade water) using an Ultimate 3000 RSLC nano UHPLC system. After a 5 min wash at 5 772 
µl/min the sample was then eluted onto an EasySpray PepMap RSLC C18 column (75 µm x 773 
50 cm, Thermo Scientific) into a LTQ Orbitrap Velos Pro via an EasySpray ion source. The 774 
peptides were eluted from the column using a flow rate of 300 nl/min and a linear gradient 775 
from 2% to 40% buffer B (0.08% formic acid in 80% MS grade CH3CN) over 124 min. The 776 
column temperature was set at 50 oC.  The Orbitrap Velos Pro ms system was operated in 777 
data dependant acquisition mode using a Top 15 method with Lockmass = 445.120024. A 778 
MS1 survey scan with a range of 335–1800 m/z and a resolution of 60,000 was followed by 779 
15 sequential MS2 scans at the normal scan rate using the LTQ Velos ion trap. The FTMS 780 
and ITMS AGC targets were set to 1e6 ions and 5e3 ions respectively. The FTMS and ITMS 781 
maximum fill times were set to 500 msec and 100 msec respectively. ITMS isolation width 782 
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was set at 2 Da with a normalised collision energy of 35, a default charge state of 2, an 783 
Activation Q of 0.250 and Activation Time of 10 msec. 784 
Peptide and protein identification. The resultant raw data was searched against the Sprot 785 
database with a taxonomy filter set to H. sapiens using the Mascot v. 2.4.1 (Matrix Science) 786 
search engine to identify peptides containing Lysines with εN-linked di-glycine 787 
modifications. Peptide mass tolerance was set to 10 ppm and the fragment mass tolerance set 788 
to 0.6 Da. The number of maximum miss-cleavages was set to 2. The enzyme was set to 789 
Trypsin/P and the following variable modifications were considered: Acetyl (N-term), 790 
Deamidated (NQ), Dioxidation (M), Gln->pyro-Glu (N-term Q), GlyGly (K), Oxidation (M).  791 
A fixed modification for Cysteine was set to N-ethylmaleimide. A mascot ion score threshold 792 
was set at 37 to filter non-significant peptide identifications. 793 
Statistical methods. No statistical methods were used to predetermine sample size. The 794 
experiments were not randomized, and the investigators were not blinded to allocation during 795 
experiments and outcome assessment. For all experiments, number of replicates (n), mean 796 
value, error value and P value cutoffs are described in the respective figure legends. Error 797 
bars are shown for all data points with replicates as a measure of variation with the group. All 798 
t-tests performed were two-tailed t-tests assuming equal variances. 799 
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α =           ; ΔpKd = pKd
T,A – pKd
A , cooperativity
N = 0.880 ± 0.004 sites
Kd = 67 ± 8 nM
ΔH = –7,980 ± 60 cal/mol
ΔS = 6.0 cal/mol/deg
N = 0.991 ± 0.001 sites
Kd = 4.4 ± 1.0 nM
ΔH = –8,960 ± 30 cal/mol
ΔS = 8.2 cal/mol/deg
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α < 1; ΔpKd < 0 , negative cooperativity
α = 1; ΔpKd = 0 , no cooperativity
















































































ZA loop BC loopαB αCαA
VHL
Brd4BD2

















































































































































































• Negative or no 








• Effective and selective
  target degradationligand-induced
PPIs
